

PCTWORLD INTELLECTUAL PROPERTY
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9605224A1

(51) International Patent Classification ⁶ : C07K 14/59, 16/26, C12P 21/00, C12N 5/10, 1/21, 15/16, 15/63		A1	(11) International Publication Number: WO 96/05224 (43) International Publication Date: 22 February 1996 (22.02.96)
(21) International Application Number: PCT/US95/09664 (22) International Filing Date: 1 August 1995 (01.08.95)		(81) Designated States: AU, BR, CA, CN, FI, HU, JP, KR, MX, NO, RU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(30) Priority Data: 08/289,396 12 August 1994 (12.08.94) US 08/310,590 22 September 1994 (22.09.94) US 08/334,629 4 November 1994 (04.11.94) US 08/351,591 7 December 1994 (07.12.94) US			
(71) Applicant: WASHINGTON UNIVERSITY [US/US]; One Brookings Drive, St. Louis, MO 63130 (US). (72) Inventor: BOIME, Irving; 27 Oak Park Drive, St. Louis, MO 63141 (US). (74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foerster, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006 (US).			

(54) Title: SINGLE-CHAIN FORMS OF THE GLYCOPROTEIN HORMONE QUARTET

(57) Abstract

Single-chain forms of the glycoprotein hormone quartet, at least some members of which are found in most vertebrates, are disclosed. In one embodiment of these single-chain forms, the α and β subunits of the wild-type heterodimers or their variants are covalently linked, optionally through a linker moiety. A drug may further be included within the linker moiety to be targeted to receptors for these hormones. Some of the single-chain forms are agonists and others antagonists of the glycoprotein hormone activity. Another embodiment of the single-chain compounds of the invention comprises two β subunits of the glycoprotein hormones, which β subunits are the same or different. These "two- β " forms are antagonists of glycoprotein hormone activity.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

SINGLE-CHAIN FORMS OF THE GLYCOPROTEIN HORMONE QUARTETAcknowledgment of Government Support

This invention was made with government support under NIH Contract No. NO1-HD-9-2922, awarded by the National
5 Institutes of Health. The government has certain rights in this invention.

Technical Field

The invention relates to the field of protein engineering and the glycoprotein hormones which occur normally
10 as heterodimers. More specifically, the invention concerns single-chain forms of chorionic gonadotropin (CG), thyroid stimulating hormone (TSH), luteinizing hormone (LH), and follicle stimulating hormone (FSH).

Background Art

15 In humans, four important glycoprotein hormone heterodimers (LH, FSH, TSH and CG) have identical α subunits and differing β subunits. Three of these hormones are present in virtually all other vertebrate species as well; CG has so far been found only in primates and in horse placenta and urine.

20 PCT application WO90/09800, published 7 September 1990, and incorporated herein by reference, describes a number of modified forms of these hormones. One important modification is C-terminal extension of the β subunit by the carboxy terminal peptide of human chorionic gonadotropin or a variant thereof.

25 Other muteins of these hormones are also described. The relevant positions for the CTP are from any one of positions 112-118 to position 145 of the β subunit of human chorionic gonadotropin. The PCT application describes variants of the CTP extension obtained by conservative amino acid substitutions such
30 that the capacity of the CTP to alter the clearance characteristics is not destroyed. In addition, U.S. Serial No. 08/049,869 filed 20 April 1993, incorporated herein by reference, describes modifying these hormones by extension or
35 CTP fragments shorter than the sequence extending from positions 112-118 to 145.

The CTP-extended β subunit of FSH is also described in two papers by applicants herein: LaPolt, P.S. et al.; Endocrinology (1992) 131:2514-2520 and Fares, F.A. et al.; Proc Natl Acad Sci USA (1992) 89:4304-4308. Both of these papers are
5 incorporated herein by reference.

The crystal structure of the heterodimeric form of human chorionic gonadotropin has now been published in more or less contemporaneous articles; one by Lapthorn, A.J. et al. Nature (1994) 369:455-461 and the other by Wu, H. et al. Structure (1994) 2:545-558. The results of these articles are
10 summarized by Patel, D.J. Nature (1994) 369:438-439.

At least one instance of preparing a successful single-chain form of a heterodimer is now known. The naturally occurring sweetener protein, monellin, is isolated from
15 serendipity berries in a heterodimeric form. Studies on the crystal structure of the heterodimer were consistent with the proposition that the C-terminus of the B chain could be linked to the N-terminus of the A chain through a linker which preserved the spatial characteristics of the heterodimeric form.
20 Such a linkage is advantageous because, for use as a sweetener protein, it would be advantageous to provide this molecule in a form stable at high temperatures. This was successfully achieved by preparing the single-chain form, thus impeding heat denaturation, as described in U.S. patent 5,264,558.

25 PCT application WO91/16922 published 14 November 1991 describes a multiplicity of chimeric and otherwise modified forms of the heterodimeric glycoprotein hormones. In general, the disclosure is focused on chimeras of α subunits or β subunits involving portions of various α or β chains
30 respectively. One construct simply listed in this application, and not otherwise described, fuses substantially all of the β chain of human chorionic gonadotropin to the α subunit preprotein, i.e., including the secretory signal sequence for this subunit. This construct falls outside the scope of the
35 present invention since the presence of the signal sequence intervening between the β and α chains fails to serve as a linker moiety as defined and described herein.

It has now been found that the normally heterodimeric glycoprotein hormones retain their properties when in single-

chain form, including single-chain forms that contain the various CTP extensions and insertions described above.

Disclosure of the Invention

The invention provides single-chain forms of the glycoprotein hormones, at least some of which hormones are found in most vertebrate species. The single-chain forms of the invention may either be glycosylated, partially glycosylated, or nonglycosylated and the α and β chains (or α and α or β and β) that occur in the native glycoprotein hormones or variants of them may optionally be linked through a linker moiety. Particularly preferred linker moieties include the carboxy terminal peptide (CTP) unit either as a complete unit or only as a portion thereof. The resulting single-chain hormones either retain the activity of the unmodified heterodimeric form or are antagonists of this activity.

Thus, in one aspect, the invention is directed to a glycosylated or nonglycosylated protein which comprises the amino acid sequence of the α subunit common to the glycoprotein hormones linked covalently, optionally through a linker moiety, to the amino acid sequence of the β subunit of one of said hormones, or variants of said amino acid sequences wherein said variants are defined herein.

In another aspect, the invention is directed to a glycosylated or nonglycosylated protein which comprises the amino acid sequence of the β subunit of a member of the glycoprotein hormone quartet linked covalently, optionally through a linker moiety, to the amino acid sequence of the β subunit of one of said hormones, or variants of said amino acid sequences wherein said variants are defined herein.

In another aspect, the invention is directed to a glycosylated or nonglycosylated protein which comprises the amino acid sequence of the α subunit of the glycoprotein hormone quartet linked covalently, optionally through a linker moiety, to the amino acid sequence of another α subunit, or variants of said amino acid sequences wherein said variants are defined herein.

In still another aspect, the invention is directed to glycosylated or nonglycosylated single-chain forms of the

biologically important dimers whose efficacy is presaged by the single-chain forms of the hormone quartet. Thus, the invention is also directed to the single-chain forms of interleukins 3 and 12 (IL-3 and IL-12), tumor necrosis factor (TNF), transforming growth factor (TGF) as well as inhibin. Also included are hybrid interleukins such as single chain forms of one subunit from IL-3 and the other from IL-12.

In other aspects, the invention is directed to recombinant materials and methods to produce the single-chain proteins of the invention, to pharmaceutical compositions containing them; to antibodies specific for them; and to methods for their use.

Brief Description of the Drawings

Figure 1 shows the construction of a SalI bounded DNA fragment fusing the third exon of CG β with the second exon encoding the α subunit.

Figure 2 shows the amino acid sequence and numbering of positions 112-145 of human CG β .

Figure 3 shows the results of a competition binding assay for FSH receptor by various FSH analogs.

Figure 4 shows the results of signal transduction assay with respect to FSH receptor for various FSH analogs.

Modes of Carrying Out the Invention

Four "glycoprotein" hormones in humans provide a family which includes human chorionic gonadotropin (hCG), follicle stimulating hormone (FSH), luteinizing hormone (LH), and thyroid stimulating hormone (TSH). As used herein, "glycoprotein hormones" refers to the members of this family, whether found in humans or in other vertebrates. All of these hormones are heterodimers comprised of α subunits which, for a given species, are identical in amino acid sequence among the group, and β subunits which differ according to the member of the family. Thus, normally these glycoprotein hormones occur as heterodimers composed of α and β subunits associated with each other but not covalently linked. Most vertebrates produce FSH, TSH and LH; chorionic gonadotropin has been found only in primates, including humans, and horses. A specific form of CG

from horses has been designated pregnant mare serum glycoprotein (PMSG).

Thus, this hormone "quartet" is composed of heterodimers wherein the α and β subunits of each are encoded in different genes and are separately synthesized by the host. The host then assembles the separately synthesized subunits into a non-covalently linked heterodimeric complex. In this manner, the heterodimers of this hormone quartet differ from heterodimers such as insulin which is synthesized from a single gene (in this case with an intervening "pro" sequence) and the subunits are covalently coupled using disulfide linkages. This hormone quartet is also distinct from the immunoglobulins which are assembled from different loci, but are covalently bound through disulfide linkages. On the other hand, monellin, which is, however, a plant protein, is held together through noncovalent interaction between its A and B chains. It is not known at present whether the two chains are encoded on separate genes.

Thus, a variety of factors is influential in determining the behavior of biologically active compounds which are dimers formed from subunits that are identical or different. The subunits may be covalently or noncovalently linked; they may be synthesized by the same or different genes; and they may or may not contain, in their precursor forms, a "pro" sequence linking the two members of the dimer. Based on the results obtained with the single-chain forms of the glycoprotein hormone quartet herein, it is apparent that single-chain forms of the biologically active dimers interleukin-12, interleukin-3 (IL-12 and IL-3), inhibin, tumor necrosis factor (TNF), and transforming growth factor (TGF) will also be biologically active.

The single-chain forms of the heterodimers or homodimers have a number of advantages over their dimeric forms. First, they are generally more stable. LH, in particular, is noted for its instability and short half-life. Second, problems of recombinant production are reduced since only a single gene need be transcribed, translated and processed. This is particularly important for expression in bacteria. Third, of course, they provide an alternate form thus permitting fine

- 6 -

tuning of activity levels and of *in vivo* half lives. Finally, single chain forms are unique starting materials for identifying truncated forms with the activity of the dimer. The linkage between the subunits permits the protein to be engineered
5 without disturbing the overall folding of the protein.

Features of the Members of the Quartet

The β subunit of hCG is substantially larger than the other β subunits in that it contains approximately 34 additional amino acids at the C-terminus referred to herein as the carboxy
10 terminal portion (CTP) which, when glycosylated at the O-linked sites, is considered responsible for the comparatively longer serum half-life of hCG as compared to other gonadotropins (Matzuk, M. et al., Endocrinol (1989) 126:376). In the native hormone, this CTP extension contains four mucin-like O-linked
15 oligosaccharides.

In one embodiment of the present invention, the α and β chains of the glycoprotein hormones are coupled into a single-chain proteinaceous material where the α and β chain are covalently linked, optionally through a linker moiety. The
20 linker moiety may include further amino acid sequence, and in particular the CTP units described herein can be advantageously included in the linker. In addition, the linker may include peptide or nonpeptide drugs which can be targeted to the receptors for the hormones.

25 In addition to the head-to-tail configuration that is achievable by simply coupling the two peptide chains through a peptide bond, the α and β chains can be linked head-to-head or tail-to-tail. Head to head and tail to tail couplings involve synthetic chemistry using standard techniques to link two
30 carboxyl or two amino groups through a linker moiety. For example, two amino groups may be linked through an anhydride or through any dicarboxylic acid derivative; two carboxyl groups can be linked through diamines or diols using standard activation techniques. However, the most preferred form is a
35 head to tail configuration wherein standard peptide linkages suffice and the single-chain compound can be prepared as a fusion protein recombinantly or using synthetic peptide techniques either in a single chain or, preferably, ligating

- 7 -

individual portions of the entire sequence. Of course, if desired, peptide or non-peptide linker moieties can be used in this case as well, but this is unnecessary and the convenience of recombinant production of the single-chain protein would suggest that embodiments that permit this method of production comprise by far the most preferred approach.

When a head-to-tail configuration is employed, linkers may consist essentially of additional peptide sequence. As is the case with the heterodimers, the two β chains may be linked through a CTP unit as further described below. Thus, possible embodiments of the invention include, with the N-terminus at the left, α -FSH β , β FSH- α , α - β LH, α -CTP- β LH, β LH-CTP- α , CTP- β LH-CTP- α ; and the like.

The single chain forms of the heterodimeric gonadotropins or glycoprotein quartet also relate to additional important sets of embodiments wherein rather than coupling the α and β subunits, two β or two α subunits may be coupled together to form a single-chain compound. As with the hetero-dimer, the coupling can be head to head, head to tail, or tail to tail.

The "two- β " single-chain tandem peptides are especially useful as antagonists for the receptors normally activated by the heterodimeric glycoprotein hormones. Since the α subunit is believed largely responsible for signal transduction, while β subunit confers receptor specificity, and since the α and β subunits have similar conformations, the single-chain compounds should be able specifically to bind a receptor for which at least one β chain is present without activating the receptor.

The antagonist activity of the "2- β " single-chain tandem peptides is based in part on the crystal structure of the heterodimers. It is noted that the α and β chains have similar cystine-knot configurations and that some of the folding patterns of the two chains are analogous.

The "two- β " single-chain compounds of the invention may be designed to contain tandem copies of the same β subunit -- i.e., FSH β -FSH β ; HCG β -HCG β ; TSH β -TSH β ; or LH β -LH β ; or chimeric single-chain compounds may be employed such as HCG β -FSH β ; FSH β -LH β ; LH β -TSH β and the like. There are a total of 12 such possible combinations. In addition, the carboxyl terminal

peptide (CTP) of the HCG β subunit improves the conformation of the single-chain compound when present between the two β chains. This is automatic when HCG β is the upstream portion; however in other instances, it is convenient to employ a CTP subunit as described herein at the carboxyl terminus of the upstream participant. Two such CTP units are also included within the invention scope. Thus, preferred embodiments include FSH β -CTP-FSH β ; FSH β -CTP-CTP-FSH β ; LH β -CTP-FSH β ; LH β -CTP-CTP-FSH β and the like.

Similar descriptions apply to the "two α " single chain compounds, except, of course, that chimeric pairs are not included other than with respect to α variants. Various linkers, preferably CTP-based, and CTP extensions are also included.

The following definitions may be helpful in describing the single-chain forms of the molecules.

As used herein, α subunit, and FSH, LH, TSH, and CG β subunits as well as the heterodimeric forms have in general their conventional definitions and refer to the proteins having the amino acid sequences known in the art *per se*, or allelic variants thereof, regardless of the glycosylation pattern exhibited.

"Native" forms of these peptides are those which have the amino acid sequences isolated from the relevant vertebrate tissue, and have these known sequences *per se*, or their allelic variants.

"Variant" forms of these proteins are those which have deliberate alterations in amino acid sequence of the native protein produced by, for example, site-specific mutagenesis or by other recombinant manipulations, or which are prepared synthetically.

These alterations consist of 1-10, preferably 1-8, and more preferably 1-5 amino acid changes, including deletions, insertions, and substitutions, most preferably conservative amino acid substitutions as defined below. The resulting variants must retain activity which affects the corresponding activity of the native hormone -- i.e., either they must retain the biological activity of the native hormone directly, or they must behave as antagonists, generally by virtue of being able to

- 9 -

bind the receptors for the native hormones but lacking the ability to effect signal transduction. For example, it is known that if the glycosylation site at position 52 of the α subunit is removed by an amino acid substitution, therefore preventing all glycosylation at that site, the hormones which are heterodimers with this altered α subunit are generally agonists and are able to bind receptors preventing the native hormone from doing so in competition. (On the other hand, the glycosylation site of the α subunit at position 78 appears not greatly to affect the activity of the hormones.) Other alterations in the amino acid sequence may also result in antagonist rather than agonist activity for the variant.

One set of preferred variants are those wherein the glycosylation sites of either the α or β subunits or both have been altered. The α subunit contains two glycosylation sites, one at position 52 and the other at position 78, and the effect of alterations of these sites on activity has just been described. Similarly, the β subunits generally contain two N-linked glycosylation sites (at positions that vary somewhat with the nature of the β chain) and similar alterations can be made at these sites. The CTP extension of hCG contains four O-linked glycosylation sites, and conservative mutations at the serine residues (e.g., conversion of the serine to alanine) destroys these sites. Destruction of the O-linked glycosylation sites may effect conversion of against activity to antagonist activity.

Finally, alterations in amino acid sequence that are proximal to the N-linked or O-linked glycosylation sites influence the nature of the glycosylation that is present on the resulting molecule and also alter activity.

Alterations in amino acid sequence also include both insertions and deletions. Thus, truncated forms of the hormones are included among variants, e.g., mutants of the α subunit which are lacking some or all of the amino acids at positions 85-92 at the C-terminus. In addition, α subunits with 1-10 amino acids deleted from the N-terminus are included. Some useful variants of the hormone quartet described herein are set forth in U.S. Patent 5,177,193 issued 5 January 1993 and incorporated herein by reference. As shown therein, the

glycosylation patterns can be altered by destroying the relevant sites or, in the alternative, by choice of host cell in which the protein is produced.

As explained above, the single chain forms are
5 convenient starting materials for various engineered muteins. Such muteins include those with non-critical regions altered or removed. Such deletions and alterations may comprise entire loops, so that sequences of considerably more than 10 amino acids may be deleted or changed. The single chain molecules
10 must, however, retain at least the receptor binding domains and/or the regions involved in signal transduction.

There is considerable literature on variants of the hormone quartet described herein and it is clear from this literature that a large number of possible variants which result
15 both in agonist and antagonist activity can be prepared. Such variants are disclosed, for example, in Chen, F. et al. Molec Endocrinol (1992) 6:914-919; Yoo, J. et al. J Biol Chem (1993) 268:13034-13042; Yoo, J. et al. J Biol Chem (1991) 266:17741-17743; Puett, D. et al. Glycoprotein Hormones, Lusbader, J.W. et
20 al. EDS, Springer Verlag New York (1994) 122-134; Kuetmann, H.T. et al. (ibid) pages 103-117; Erickson, L.D. et al. Endocrinology (1990) 126:2555-2560; and Bielinska, M. et al. J Cell Biol (1990) 111:330a (Abstract 1844).

As described hereinabove, one method of constructing
25 effective antagonists is to prepare a single-chain molecule containing two β subunits of the same or different member of the glycoprotein quartet. Particularly preferred variants of these single-chain forms include those wherein one or more cystine-link is deleted, typically by substituting a neutral amino acid
30 for one or both cysteines which participate in the link. Particularly preferred cystine links which may be deleted are those between positions 26 and 110 and between positions 23 and 72.

In addition, it has been demonstrated that the β
35 subunits of the hormone quartet can be constructed in chimeric forms so as to provide biological functions of both components of the chimera, or, in general, hormones of altered biological function. Thus, chimeric molecules which exhibit both FSH and LH/CG activities can be constructed as described by Moyle, Proc

Natl Acad Sci (1991) 88:760-764; Moyle, Nature (1994) 368:251-255. As disclosed in these papers, substituting amino acids 101-109 of FSH- β for the corresponding residues in the CG- β subunit yields an analog with both hCG and FSH activity.

5 These chimeric forms of β subunits can also be used in the single-chain compounds which couple two β subunits into a single molecule.

 Although it is recognized that glycosylation pattern has a profound influence on activity both qualitatively and
10 quantitatively, for convenience the terms FSH, LH, TSH, and CG β subunits refers to the amino acid sequence characteristic of the peptides, as does " α subunit." When only the β chain is referred to, the terms will be, for example, FSH β ; when the heterodimer is referred to, the simple term "FSH" will be used.
15 It will be clear from the context in what manner the glycosylation pattern is affected by, for example, recombinant expression host or alteration in the glycosylation sites. Forms of the glycoprotein with specified glycosylation patterns will be so noted.

20 As used herein "peptide" and "protein" are used interchangeably, since the length distinction between them is arbitrary.

 In the single-chain forms of the present invention, the α and/or β chain may contain a CTP extension inserted into a
25 noncritical region.

 "Noncritical" regions of the α and β subunits are those regions of the molecules not required for biological activity (including agonist and antagonist activity). In general, these regions are removed from binding sites, precursor
30 cleavage sites, and catalytic regions. Regions critical for inducing proper folding, binding to receptors, catalytic activity and the like should be avoided; similarly, regions which are critical to assure the three-dimensional conformation of the protein should be avoided. It should be noted that some
35 of the regions which are critical in the case of the dimer become non-critical in the single chain forms since the conformational restriction imposed by the single chain may obviate the necessity for these regions. The ascertainment of noncritical regions is readily accomplished by deleting or

modifying candidate regions and conducting an appropriate assay for the desired activity. Regions where modifications result in loss of activity are critical; regions wherein the alteration results in the same or similar activity (including antagonist
5 activity) are considered noncritical.

It should be emphasized, that by "biological activity" is meant activity which is either agonistic or antagonistic to that of the native hormones. Thus, certain regions are critical for behavior of a variant as an antagonist, even though the
10 antagonist is unable to directly provide the physiological effect of the hormone.

For example, for the α subunit, positions 33-59 are thought to be necessary for signal transduction and the 20 amino acid stretch at the carboxy terminus is needed for signal
15 transduction/receptor binding. Residues critical for assembly with the β subunit include at least residues 33-58, particularly 37-40.

Where the noncritical region is "proximal" to the N- or C-terminus, the insertion is at any location within 10 amino
20 acids of the terminus, preferably within 5 amino acids, and most preferably at the terminus *per se*.

In general, "proximal" is used to indicate a position which is within 10 amino acids, preferably within five amino acids, of a referent position, and most preferably at the
25 referent position *per se*. Thus, certain variants may contain substitutions of amino acids "proximal" to a glycosylation site; the definition is relevant here. In addition, the α and β subunits may be linked to each other at positions "proximal" to their N- or C-termini.

30 As used herein, the "CTP unit" refers to an amino acid sequence found at the carboxy terminus of human chorionic gonadotropin β subunit which extends from amino acid 112-118 to residue 145 at the C-terminus or to a portion thereof. Thus, each "complete" CTP unit contains 28-34 amino acids, depending
35 on the N-terminus of the CTP. The native sequence of positions 112-145 is shown in Figure 2.

By a "partial" CTP unit is meant an amino acid sequence which occurs between positions 112-118 to 145 inclusive, but which has at least one amino acid deleted from

- 13 -

the shortest possible "complete" CTP unit (i.e. from positions 118-145). The "partial" CTP units included in the invention preferably contain at least one O-glycosylation site if agonist activity is desired. Some nonglycosylated forms of the hormones are antagonists and are useful as such. The CTP unit contains four such sites at the serine residues at positions 121 (site 1); 127 (site 2); 132 (site 3); and 138 (site 4). The partial forms of CTP useful in agonists of the invention will contain one or more of these sites arranged in the order in which they appear in the native CTP sequence. Thus, the "partial" CTP unit employed in agonists of the invention may include all four glycosylation sites; sites 1, 2 and 3; sites 1, 2 and 4; sites 1, 3 and 4; sites 2, 3 and 4; or simply sites 1 and 2; 1 and 3; 1 and 4; 2 and 3; 2 and 4; or 3 and 4; or may contain only one of sites 1, 2, 3 or 4.

By "tandem" inserts or extensions is meant that the insert or extension contains at least two "CTP units". Each CTP unit may be complete or a fragment, and native or a variant. All of the CTP units in the tandem extension or insert may be identical, or they may be different from each other. Thus, for example, the tandem extension or insert may generically be partial-complete; partial-partial; partial-complete-partial; complete-complete-partial, and the like wherein each of the noted partial or complete CTP units may independently be either a variant or the native sequence.

The "linker moiety" is a moiety that joins the α and β sequences without interfering with the activity that would otherwise be exhibited by the same α and β chains as members of a heterodimer, or which alters that activity to convert it from agonist to antagonist activity. The level of activity may change within a reasonable range, but the presence of the linker cannot be such so as to deprive the single-chain form of both substantial agonist and substantial antagonist activity. The single-chain form must remain as a single-chain form when it is recovered from its production medium and must exhibit activity pertinent to the hormonal activity of the heterodimer, the elements of which form its components.

Variants

The hormone subunits and the CTP units may correspond exactly to the native hormone or CTP sequence, or may be variants. The nature of the variants has been defined hereinabove. In such variants, 1-10, preferably 1-8, and most preferably 1-5 of the amino acids contained in the native sequence are substituted by a different amino acid compared to the native amino acid at that position, or 1-10, more preferably 1-8 and most preferably 1-5 amino acids are simply deleted or combination of these. As pointed out above, when non-critical regions of the single chain forms are identified, in particular, through detecting the presence of non-critical "loops", the number of amino acids altered by deletion or substitution may be increased to 20 or 30 or any arbitrary number depending on the length of amino acid sequence in the relevant non-critical region. Of course, deletion or substitutions in more than one non-critical region results in still greater numbers of amino acids in the single chain forms being affected and substitution and deletions strategies may be used in combination. The substitutions or deletions taken cumulatively do not result in substantial elimination of agonist or antagonist activity associated with the hormone. Substitutions by conservative analogs of the native amino acid are preferred.

"Conservative analog" means, in the conventional sense, an analog wherein the residue substituted is of the same general amino acid category as that for which substitution is made. Amino acids have been classified into such groups, as is understood in the art, by, for example, Dayhoff, M. et al., Atlas of Protein Sequences and Structure (1972) 5:89-99. In general, acidic amino acids fall into one group; basic amino acids into another; neutral hydrophilic amino acids into another; and so forth.

More specifically, amino acid residues can be generally subclassified into four major subclasses as follows:

35 Acidic: The residue has a negative charge due to loss of H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH.

Basic: The residue has a positive charge due to association with H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH.

Neutral/nonpolar: The residues are not charged at physiological pH and the residue is repelled by aqueous solution so as to seek the inner positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium. These residues are also designated "hydrophobic" herein.

Neutral/polar: The residues are not charged at physiological pH, but the residue is attracted by aqueous solution so as to seek the outer positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium.

It is understood, of course, that in a statistical collection of individual residue molecules some molecules will be charged, and some not, and there will be an attraction for or repulsion from an aqueous medium to a greater or lesser extent. To fit the definition of "charged," a significant percentage (at least approximately 25%) of the individual molecules are charged at physiological pH. The degree of attraction or repulsion required for classification as polar or nonpolar is arbitrary and, therefore, amino acids specifically contemplated by the invention have been classified as one or the other. Most amino acids not specifically named can be classified on the basis of known behavior.

Amino acid residues can be further subclassified as cyclic or noncyclic, and aromatic or nonaromatic, self-explanatory classifications with respect to the side chain substituent groups of the residues, and as small or large. The residue is considered small if it contains a total of 4 carbon atoms or less, inclusive of the carboxyl carbon. Small residues are, of course, always nonaromatic.

For the naturally occurring protein amino acids, subclassification according to the foregoing scheme is as follows.

- 16 -

Acidic: Aspartic acid and Glutamic acid;

Basic/noncyclic: Arginine, Lysine;

Basic/cyclic: Histidine;

5 Neutral/polar/small: Glycine, serine,
cysteine;

Neutral/nonpolar/small: Alanine;

Neutral/polar/large/nonaromatic: Threonine,
Asparagine, Glutamine;

Neutral/polar/large aromatic: Tyrosine;

10 Neutral/nonpolar/large/nonaromatic: Valine,
Isoleucine, Leucine, Methionine;

Neutral/nonpolar/large/aromatic: Phenylalanine, and
Tryptophan.

The gene-encoded secondary amino acid proline,
15 although technically within the group neutral/nonpolar/
large/cyclic and nonaromatic, is a special case due to its known
effects on the secondary conformation of peptide chains, and is
not, therefore, included in this defined group.

If the single-chain proteins of the invention are
20 constructed by recombinant methods, they will contain only gene
encoded amino acid substitutions; however, if any portion is
synthesized by standard, for example, solid phase, peptide
synthesis methods and ligated, for example, enzymatically, into
the remaining protein, non-gene encoded amino acids, such as
25 aminoisobutyric acid (Aib), phenylglycine (Phg), and the like
can also be substituted for their analogous counterparts.

These non-encoded amino acids also include, for
example, β -alanine (β -Ala), or other omega-amino acids, such as
3-amino propionic, 4-amino butyric and so forth, sarcosine
30 (Sar), ornithine (Orn), citrulline (Cit), t-butylalanine

- 17 -

(t-BuA), t-butylglycine (t-BuG), N-methylisoleucine (N-MeIle), and cyclohexylalanine (Cha), norleucine (Nle), cysteic acid (Cya) 2-naphthylalanine (2-Nal); 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic); mercaptovaleric acid (Mvl); β -2-thienylalanine (Thi); and methionine sulfoxide (MSO). These also fall conveniently into particular categories.

Based on the above definitions,

Sar and β -Ala and Aib are neutral/nonpolar/ small;

t-BuA, t-BuG, N-MeIle, Nle, Mvl and Cha are

10 neutral/nonpolar/large/nonaromatic;

Orn is basic/noncyclic;

Cya is acidic;

Cit, Acetyl Lys, and MSO are neutral/polar/
large/nonaromatic; and

15 Phg, Nal, Thi and Tic are neutral/nonpolar/large/
aromatic.

The various omega-amino acids are classified according to size as neutral/nonpolar/small (β -Ala, i.e., 3-aminopropionic, 4-aminobutyric) or large (all others).

20 Thus, amino acid substitutions other than those encoded in the gene can also be included in peptide compounds within the scope of the invention and can be classified within this general scheme according to their structure.

Preferred Embodiments of the Single-Chain Hormones

25 The single-chain hormones of the invention are most efficiently and economically produced using recombinant techniques. Therefore, those forms of α and β chains, CTP units and other linker moieties which include only gene-encoded amino acids are preferred. It is possible, however, as set forth
30 above, to construct at least portions of the single-chain hormones using synthetic peptide techniques or other organic synthesis techniques and therefore variants which contain nongene-encoded amino acids are also within the scope of the invention.

35 In the most preferred embodiments of the single-chain hormones of the invention, the C-terminus of the β subunit is covalently linked, optionally through a linker, to the N-terminus of the mature α subunit; forms wherein the C-terminus

of the α subunit is linked to the N-terminus of the β subunit are also useful, but may have less activity either as antagonists or agonists of the relevant receptor. The linkage can be a direct peptide linkage wherein the C-terminal amino acid of one subunit is directly linked through the peptide bond to the N-terminus of the other; however, in many instances it is preferable to include a linker moiety between the two termini. In many instances, the linker moiety will provide at least one β turn between the two chains. The presence of proline residues in the linker may therefore be advantageous.

As described above, the N-terminus of the α chain may also be coupled to the N-terminus of the β chain or the C-terminus of the α to the C-terminus of the β chain in any case through a linker unit, similar combinations are included in the single chain forms comprising two α or two β subunits.

It should be understood that in discussing linkages between the termini of the subunits comprising the single chain forms, one or more termini may be altered by substitution and/or deletion as described above.

Preferred embodiments of the single-chain compounds containing two β subunits are those wherein the C-terminus of one unit is linked to the N-terminus of the other, optionally through a linker, preferably a peptide linker. Also possible, as described above, are linkages between the N-termini of the two β chains or linkages between the C-termini of the two β chains; in these cases, of course, a linker is required.

While the head-to-head, tail-to-tail and head-to-tail configurations of both the single-chain heterodimer and the single-chain two- β subunit form have been described, the linkage between the two subunits may also occur at positions not precisely at the N- or C-terminus of each member but at positions proximal thereto.

In one particularly preferred set of embodiments, the linkage is head-to-tail and the linker moiety will include one or more CTP units and/or variants or truncated forms thereof. Preferred forms of the CTP units used in such linker moieties are described hereinbelow.

Further, the linker moiety may include a drug covalently, preferably releasably, bound to the linker moiety.

- 19 -

Means for coupling the drug to the linker moiety and for providing for its release are conventional.

In addition to their occurrence in the linker moiety, CTP and its variants and truncations may also be included in any noncritical region of the subunits making up the single-chain hormone. The nature of these inclusions, and their positions, is set forth in detail in the parent application herein.

While CTP units are preferred inclusions in the linker moiety, it is understood that the linker may be any suitable covalently bound material which provides the appropriate spatial relationship between the α and β subunits. Thus, for head-to-tail configurations the linker may generally be a peptide comprising an arbitrary number, but typically less than 100, more preferably less than 50 amino acids which has the proper hydrophilicity/hydrophobicity ratio to provide the appropriate spacing and confirmation in solution. In general, the linker should be on balance hydrophilic so as to reside in the surrounding solution and out of the way of the interaction between the α and β subunits or the two β subunits. It is preferable that the linker include β turns typically provided by proline residues. Any suitable polymer, including peptide linkers, with the above-described correct characteristics may be used.

One particular linker moiety that is not included within the scope of the invention is that which includes a signal peptide immediately upstream of the downstream subunit.

Particularly preferred embodiments of the single-chain hormones of the invention include:

β FSH- α ; β FSH- β FSH; β FSH- β LH;
 β LH- α ; β LH- β LH; β LH- β FSH;
 β TSH- α ; β TSH- β TSH; β TSH- β FSH;
 β CG- α ; β -CG- β -CG; β CG- β FSH; β CG- β TSH;
 β FSH-CTP- α ; β FSH-CTP- β FSH; β FSH-CTP- β LH;
 β LH-CTP- α ; β LH-CTP- β LH; β LH-CTP- β FSH;
 β CG-CTP- α ; β FSH-CTP-CTP- β LH;
 β FSH-CTP-CTP- α ; β FSH-CTP-CTP- β TSH;
 β LH-CTP-CTP- α ; β LH-CTP-CTP- β LH;
 β CG-CTP-CTP- α ; β CG-CTP-CTP- β LH;
 α - α ; α -CTP- α ; and α -CTP-CTP- α

- 20 -

and the like. Also particularly preferred are the human forms of the subunits. In the above constructions, "CTP" refers to CTP or its variants or truncations as further explained in the paragraph below.

5 Preferred Embodiments of CTP Units

The notation used for the CTP units of the invention is as follows: for portions of the complete CTP unit, the positions included in the portion are designated by their number as they appear in Figure 2 herein. Where substitutions occur, 10 the substituted amino acid is provided along with a superscript indicating its position. Thus, for example, CTP (120-143) represents that portion of CTP extending from positions 120 to 143; CTP (120-130; 136-143) represents a fused amino acid sequence lacking positions 118-119, 131-135, and 144-145 of the 15 native sequence. CTP (Arg¹²²) refers to a variant wherein the lysine at position 122 is substituted by an arginine; CTP (Ile¹³⁴) refers to a variant wherein the leucine at position 134 is substituted by isoleucine. CTP (Val¹²⁸Val¹⁴³) represents a variant wherein two substitutions have been made, one for the 20 leucine at position 128 and the other for the isoleucine at position 142. CTP (120-143; Ile¹²⁸Ala¹³⁰) represents the relevant portion of the CTP unit where the two indicated substitutions have been made.

Also preferred among variants of CTP are those wherein 25 one or more of the O-linked glycosylation sites have been altered or deleted. One particularly preferred means of altering the site to prevent glycosylation is substitution of an alanine residue for the serine residue in these sites.

Particularly preferred are those CTP units of the 30 following formulas:

- #1 CTP (116-132)
- #2 CTP (118-128; 130-135)
- #3 CTP (117-142)
- #4 CTP (116-130)
- 35 #5 CTP (116-123; 137-145)
- #6 CTP (115-133; 141-145)
- #7 CTP (117-140, Ser¹²³Gln¹⁴⁰)
- #8 CTP (125-143, Ala¹³⁰)

- 21 -

- #9 CTP (135-145, Glu¹³⁹)
#10 CTP (131-143, Val¹⁴² Val¹⁴³)
#11 CTP (118-132)
#12 CTP (118-127)
5 #13 CTP (118-145)
#14 CTP (115-132)
#15 CTP (115-127)
#16 CTP (115-145)
#17 CTP (112-145)
10 #18 CTP (112-132)
#19 CTP (112-127)

Preferred Embodiments of the α and β Subunits

Of course, the native forms of the α and β subunits in the single-chain form are among the preferred embodiments.

15 However, certain variants are also preferred.

In particular, variants of the α subunit in which the N-linked glycosylation site at position 52 is eliminated or altered by amino acid substitutions at or proximal to this site are preferred for antagonist activity. Similar modifications at
20 the glycosylation site at position 78 are also preferred. Deletion of one or more amino acids at positions 85-92 also affects the nature of the activity of hormones containing the α subunit and substitution or deletion of amino acids at these positions is also among the preferred embodiments.

25 Similarly, the N-linked glycosylation sites in the β chain can conveniently be modified to eliminate glycosylation and thus affect the agonist or antagonist activity of the β chains. If CTP is present, either natively as in CG or by virtue of being present as a linker, the O-linked glycosylation
30 sites in this moiety may also be altered.

Particular variants containing modified or deleted glycosylation sites are set forth in Yoo, J. et al. J Biol Chem (1993) 268:13034-13042; Yoo, J. et al. J Biol Chem (1991) 266:17741-17743; and Bielinska, M. et al. J Cell Biol (1990) 111:330a (all cited above) and in Matzuk, M.M. et al. J Biol Chem (1989) 264:2409-2414; Keene, J.L. et al. J Biol Chem (1989) 264:4769-4775; and Keene, J.L. et al. Mol Endocrinol (1989) 3:2011-2017.

- 22 -

Not only may the glycosylation sites *per se* be modified directly, but positions proximal to these sites are preferentially modified so that the glycosylation status of the mutant will be affected. For the α subunit, for example,

5 variants in which amino acids between positions 50-60 are substituted, including both conservative and nonconservative substitutions, are favored, especially substitutions at positions 51, 53 and 55 because of their proximity to the glycosylation site at Asn₅₂.

10 Also preferred are mutants of the α subunit wherein lysine at position 91 is converted to methionine or glutamic acid.

Although the variants have been discussed in terms of variations in the individual subunits hereinabove, it will be recalled that the single chain forms of the dimer offer additional opportunities for modification. Specifically, regions that are critical to folding of the dimer may not be critical to the correct conformation of the single chain molecule and these regions are available for variation in the

15 single chain form, although not described above in terms of individual members of the dimeric forms. Further, the single chain forms may be modified dramatically in the context of non-critical regions whose alteration and/or deletion do not affect the biological activity as described above.

25 Suitable Drugs

Suitable drugs that may be included in the linker moiety include peptides or proteins such as insulin-like growth factors; epidermal growth factors; acidic and basic fibroblast growth factors; platelet-derived growth factors; the various

30 colony stimulating factors, such as granulocyte CSF, macrophage-CSF, and the like; as well as the various cytokines such as IL-2, IL-3 and the plethora of additional interleukin proteins; the various interferons; tumor necrosis factor; and the like. Peptide- or protein-based drugs have the advantage that they can

35 be included in the single-chain and the entire construct can readily be produced by recombinant expression of a single gene. Also, small molecule drugs such as antibiotics, antiinflammatories, toxins, and the like can be used.

- 23 -

In general, the drugs included within the linker moiety will be those desired to act in the proximity of the receptors to which the hormones ordinarily bind. Suitable provision for release of the drug from inclusion within the linker will be provided, for example, by also including sites for enzyme-catalyzed lysis as further described under the section headed Preparation Methods hereinbelow.

Other Modifications

The single-chain proteins of the invention may be further conjugated or derivatized in ways generally understood to derivatize amino acid sequences, such as phosphorylation, glycosylation, deglycosylation of ordinarily glycosylated forms, modification of the amino acid side chains (e.g., conversion of proline to hydroxyproline) and similar modifications analogous to those post-translational events which have been found to occur generally.

The glycosylation status of the hormones of the invention is particularly important. The hormones may be prepared in nonglycosylated form either by producing them in procaryotic hosts or by mutating the glycosylation sites normally present in the subunits and/or any CTP units that may be present. Both nonglycosylated versions and partially glycosylated versions of the hormones can be prepared by manipulating the glycosylation sites. Normally, glycosylated versions are, of course, also included within the scope of the invention.

As is generally known in the art, the single-chain proteins of the invention may also be coupled to labels, carriers, solid supports, and the like, depending on the desired application. The labeled forms may be used to track their metabolic fate; suitable labels for this purpose include, especially, radioisotope labels such as iodine 131, technetium 99, indium 111, and the like. The labels may also be used to mediate detection of the single-chain proteins in assay systems; in this instance, radioisotopes may also be used as well as enzyme labels, fluorescent labels, chromogenic labels, and the like. The use of such labels is particularly helpful for these proteins since they are targeting agents receptor ligand.

- 24 -

The proteins of the invention may also be coupled to carriers to enhance their immunogenicity in the preparation of antibodies specifically immunoreactive with these new modified forms. Suitable carriers for this purpose include keyhole
5 limpet hemocyanin (KLH), bovine serum albumin (BSA) and diphtheria toxoid, and the like. Standard coupling techniques for linking the modified peptides of the invention to carriers, including the use of bifunctional linkers, can be employed.

Similar linking techniques, along with others, may be
10 employed to couple the proteins of the invention to solid supports. When coupled, these proteins can then be used as affinity reagents for the separation of desired components with which specific reaction is exhibited.

Preparation Methods

15 Methods to construct the proteins of the invention are well known in the art. As set forth above, if only gene encoded amino acids are included, and the single-chain is in a head-to-tail configuration, the most practical approach at present is to synthesize these materials recombinantly by expression of the
20 DNA encoding the desired protein. DNA containing the nucleotide sequence encoding the single-chain forms, including variants, can be prepared from native sequences. Techniques for site-directed mutagenesis, ligation of additional sequences, PCR, and construction of suitable expression systems are all, by now,
25 well known in the art. Portions or all of the DNA encoding the desired protein can be constructed synthetically using standard solid phase techniques, preferably to include restriction sites for ease of ligation. Suitable control elements for transcription and translation of the included coding sequence
30 can be provided to the DNA coding sequences. As is well known, expression systems are now available compatible with a wide variety of hosts, including procaryotic hosts such as bacteria and eucaryotic hosts such as yeast, plant cells, insect cells, mammalian cells, avian cells, and the like.

35 The choice of host is particularly to posttranslational events, most particularly including glycosylation. The location of glycosylation is mostly controlled by the nature of the glycosylation sites within the

- 25 -

molecule; however, the nature of the sugars occupying this site is largely controlled by the nature of the host. Accordingly, a fine-tuning of the properties of the hormones of the invention can be achieved by proper choice of host.

5 A particularly preferred form of gene for the α subunit portion, whether the α subunit is modified or unmodified, is the "minigene" construction.

As used herein, the α subunit "minigene" refers to the gene construction disclosed in Matzuk, M.M., et al, Mol
10 Endocrinol (1988) 2:95-100, in the description of the construction of $pM^2/CG \alpha$ or pM^2/α . This "minigene" is characterized by retention only of the intron sequence between exon 3 and exon 4, all upstream introns having been deleted. In the particular construction described, the N-terminal coding
15 sequences which are derived from exon 2 and a portion of exon 3 are supplied from cDNA and are ligated directly through an XbaI restriction site into the coding sequence of exon 3 so that the introns between exons I and II and between exons II and III are absent. However, the intron between exons III and IV as well as
20 the signals 3' of the coding sequence are retained. The resulting minigene can conveniently be inserted as a BamHI/BglIII segment. Other means for construction of a comparable minigene are, of course, possible and the definition is not restricted to the particular construction wherein the coding sequences are
25 ligated through an XbaI site. However, this is a convenient means for the construction of the gene, and there is no particular advantage to other approaches, such as synthetic or partially synthetic preparation of the gene. The definition includes those coding sequences for the α subunit which retain
30 the intron between exons III and IV, or any other intron and preferably no other introns.

For recombinant production, modified host cells using expression systems are used and cultured to produce the desired protein. These terms are used herein as follows:

35 A "modified" recombinant host cell, i.e., a cell "modified to contain" with the recombinant expression systems of the invention, refers to a host cell which has been altered to contain this expression system by any convenient manner of introducing it, including transfection, viral infection, and so

forth. "Modified" refers to cells containing this expression system whether the system is integrated into the chromosome or is extrachromosomal. The "modified" cells may either be stable with respect to inclusion of the expression system or not. In short, "modified" recombinant host cells with the expression system of the invention refers to cells which include this expression system as a result of their manipulation to include it, when they natively do not, regardless of the manner of effecting this incorporation.

10 "Expression system" refers to a DNA molecule which includes a coding nucleotide sequence to be expressed and those accompanying control sequences necessary to effect the expression of the coding sequence. Typically, these controls include a promoter, termination regulating sequences, and, in 15 some cases, an operator or other mechanism to regulate expression. The control sequences are those which are designed to be functional in a particular target recombinant host cell and therefore the host cell must be chosen so as to be compatible with the control sequences in the constructed 20 expression system.

If secretion of the protein produced is desired, additional nucleotide sequences encoding a signal peptide are also included so as to produce the signal peptide operably linked to the desired single-chain hormone to produce the 25 preprotein. Upon secretion, the signal peptide is cleaved to release the mature single-chain hormone.

As used herein "cells," "cell cultures," and "cell lines" are used interchangeably without particular attention to nuances of meaning. Where the distinction between them is 30 important, it will be clear from the context. Where any can be meant, all are intended to be included.

The protein produced may be recovered from the lysate of the cells if produced intracellularly, or from the medium if secreted. Techniques for recovering recombinant proteins from 35 cell cultures are well understood in the art, and these proteins can be purified using known techniques such as chromatography, gel electrophoresis, selective precipitation, and the like.

All or a portion of the hormones of the invention may be synthesized directly using peptide synthesis techniques known

- 27 -

in the art. Synthesized portions may be ligated, and release sites for any drug contained in the linker moiety introduced by standard chemical means. For those embodiments which contain amino acids which are not encoded by the gene and those
5 embodiments wherein the head-to-head or tail-to-tail configuration is employed, of course, the synthesis must be at least partly at the protein level. Head-to-head junctions at the natural N-termini or at positions proximal to the natural N-termini may be effected through linkers which contain
10 functional groups reactive with amino groups, such as dicarboxylic acid derivatives. Tail-to-tail configurations at the C-termini or positions proximal to the C-termini may be effected through linkers which are diamines, diols, or combinations thereof.

15 Antibodies

The proteins of the invention may be used to generate antibodies specifically immunoreactive with these new compounds. These antibodies are useful in a variety of diagnostic and therapeutic applications. For example, when the single-chain
20 forms of the invention are used therapeutically in either human or veterinary contexts, the levels of drug may be monitored using these antibodies using conventional immunoassay techniques. In addition, since some of the antibodies raised by these single-chain forms are cross-reactive with the
25 heterodimer, they can be used to diagnose naturally occurring levels of the heterodimer.

The antibodies are generally prepared using standard immunization protocols in mammals such as rabbits, mice, sheep or rats, and the antibodies are titered as polyclonal antisera
30 to assure adequate immunization. The polyclonal antisera can then be harvested as such for use in, for example, immunoassays. Antibody-secreting cells from the host, such as spleen cells, or peripheral blood leukocytes, may be immortalized using known techniques and screened for production of monoclonal antibodies
35 immunospecific with the proteins of the invention.

By "immunospecific for the proteins" is meant antibodies which are immunoreactive with the single-chain proteins, but not with the heterodimers *per se* within the

general parameters considered to determine affinity or nonaffinity. It is understood that specificity is a relative term, and an arbitrary limit could be chosen, such as a difference in immunoreactivity of 100-fold or greater. Thus, an immunospecific antibody included within the invention is at least 100 times more reactive with the single-chain protein than with the corresponding heterodimers.

Formulation

The proteins of the invention are formulated and administered using methods comparable to those known for the heterodimers corresponding to the single-chain form. Thus, formulation and administration methods will vary according to the particular hormone used. However, the dosage level and frequency of administration may be altered as compared to the heterodimer, especially if CTP units are present in view of the extended biological half life due to its presence.

Formulations for proteins of the invention are those typical of protein or peptide drugs such as found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Company, Easton, PA. Generally, proteins are administered by injection, typically intravenous, intramuscular, subcutaneous, or intraperitoneal injection, or using formulations for transmucosal or transdermal delivery. These formulations generally include a detergent or penetrant such as bile salts, fusidic acids, and the like. These formulations can be administered as aerosols or suppositories or, in the case of transdermal administration, in the form of skin patches.

Oral administration is also possible provided the formulation protects the peptides of the invention from degradation in the digestive system.

Optimization of dosage regimen and formulation is conducted as a routine matter and as generally performed in the art.

Methods of Use

The single-chain peptides of the invention may be used in many ways, most evidently as substitutes for the heterodimeric forms of the hormones. Thus, like the

- 29 -

heterodimers, the agonist forms of the single-chain hormones of the invention can be used in treatment of infertility, as aids in in vitro fertilization techniques, and other therapeutic methods associated with the native hormones, both in humans and
5 in animals.

The single-chain hormones are also useful as reagents in a manner similar to the heterodimers.

In addition, the single-chain hormones of the invention may be used as diagnostic tools to detect the presence
10 or absence of antibodies with respect to the native proteins in biological samples. They are also useful as control reagents in assay kits for assessing the levels of these hormones in various samples. Protocols for assessing levels of the hormones themselves or of antibodies raised against them are standard
15 immunoassay protocols commonly known in the art. Various competitive and direct assay methods can be used involving a variety of labeling techniques including radio-isotope labeling, fluorescence labeling, enzyme labeling and the like.

The single-chain hormones of the invention are also
20 useful in detecting and purifying receptors to which the native hormones bind. Thus, the single-chain hormones of the invention may be coupled to solid supports and used in affinity chromatographic preparation of receptors or antihormone antibodies. The resulting receptors are themselves useful in
25 assessing hormone activity for candidate drugs in screening tests for therapeutic and reagent candidates.

Finally, the antibodies uniquely reactive with the single-chain hormones of the invention can be used as
purification tools for isolation of subsequent preparations of
30 these materials. They can also be used to monitor levels of the single-chain hormones administered as drugs.

The following examples are intended to illustrate but not to limit the invention.

- 30 -

Example 1Preparation of DNA Encoding CG β - α

Figure 1 shows the construction of an insert for an expression vector wherein the C-terminus of the β -chain of human CG is linked to the N-terminus of the mature human α subunit.

As shown in Figure 1, the polymerase chain reaction (PCR) is utilized to fuse the two subunits between exon 3 of CG β and exon 2 of the α subunit so that the codon for the carboxy terminal amino acid of CG β is fused directly in reading frame to that of the N-terminal amino acid of the α subunit. This is accomplished by using a hybrid primer to amplify a fragment containing exon 3 of CG β wherein the hybrid primer contains a "tail" encoding the N-terminal sequence of the α subunit. The resulting amplified fragment thus contains a portion of exon 2 encoding human CG α .

Independently, a hybrid primer encoding the N-terminal sequence of the α subunit fused to the codons corresponding to the C-terminus of CG β is used as one of the primers to amplify the α minigene. The two amplified fragments, each now containing overlapping portions encoding the other subunit are together amplified with two additional primers covering the entire span to obtain the SalI insert.

In more detail, reaction 1 shows the production of a fragment containing exon 3 of CG β and the first four amino acids of the mature α subunit as well as a SalI site 5'-ward of the coding sequences. It is obtained by amplifying a portion of the CG β genomic sequence which is described by Matzuk, M.M. et al. Proc Natl Acad Sci USA (1987) 84:6354-6358; Policastro, P. et al. J Biol Chem (1983) 258:11492-11499.

Primer 1 provides the SalI site and has the sequence:

5'-GGA GGA AGG GTG GTC GAC CTC TCT GGT-3'.
SalI

The other primer, primer 2, is complementary to four codons of the α N-terminal sequence and five codons of the CG β C-terminal sequence and has the sequence:

- 31 -

5'-CAC ATC AGG AGC | TTG TGG GAG GAT CGG-3'.

←α|β→

The resultant amplified segment which is the product of reaction I thus has a SalI site 5'-ward of the fused coding region.

In reaction II, an analogous fused coding region is obtained from the α minigene described hereinabove. Primer 3 is a hybrid primer containing four codons of the β subunit and five codons of α and has the sequence:

10 5'-ATC CTC CCA CAA | GCT CCT GAT GTG CAG-3'.

←β|α→

Primer 4 contains a SalI site and is complementary to the extension of α exon 4. Primer 4 has the sequence:

15 5'-TGA GTC GAC ATG ATA ATT CAG TGA TTG AAT-3'.

SalI

Thus, the products of reactions I and II overlap, and when subjected to PCR in the presence of primers 1 and 4 yield the desired SalI product as shown in reaction III.

The amplified fragment containing CGβ exon 3 and the α minigene is inserted into the SalI site of pM²HA-CGβexon1,2 an expression vector which is derived from pM² containing CGβ exons 1 and 2 in the manner described by Sachais, B., Snider, R.M., Lowe, J., Krause, J. J Biol Chem (1993) 268:2319. pM² containing CGβ exons 1 and 2 is described in Matzuk, M.M. et al. Proc Natl Acad USA (1987) 84:6354-6358 and Matzuk, M.M. et al. J Cell Biol (1988) 106:1049-1059.

This expression vector then will produce the single-chain form human CG wherein the C-terminus of the β subunit is directly linked to the N-terminus of the α subunit.

30

Example 2

Production and Activity of the Single-Chain Human CG

The expression vector constructed in Example 1 was transfected into Chinese hamster ovary (CHO) cells and production of the protein was assessed by immunoprecipitation of

- 32 -

radiolabeled protein on SDS gels. The culture medium was collected and the bioactivity of the single-chain protein was compared to the heterodimer in a competitive binding assay with respect to the human LH receptor. In this assay, the cDNA
5 encoding the entire human LH receptor was inserted into the expression vector pCMX (Oikawa, J. X-C et al. Mol Endocrinol (1991) 5:759-768). Exponentially growing 293 cells were transfected with this vector using the method of Chen, C. et al. Mol Cell Biol (1987) 7:2745-2752.

10 In the assay, the cells expressing human LH receptor (2×10^5 /tube) were incubated with 1 ng of labeled hCG in competition with the sample to be tested at 22°C for 18 hours. The samples were then diluted 5-fold with cold Dulbecco's PBS (2 ml) supplemented with 0.1% BSA and centrifuged at 800 x g for 15
15 minutes. The pellets were washed twice with D's PBS and radioactivity was determined with a gamma counter. Specific binding was 10-12% of the total labeled (iodinated) hCG added in the absence of sample. The decrease in label in the presence of sample measures the binding ability in the sample. In this
20 assay, with respect to the human LH receptor in 293 cells, the wild-type hCG had an ED_{50} of 0.47 ng and the single-chain protein had an ED_{50} of 1.1 ng.

In an additional assay for agonist activity, stimulation of cAMP production was assessed. In this case, 293
25 cells expressing human LH receptors (2×10^5 /tube) were incubated with varying concentrations of the heterodimeric hCG or single-chain hCG and cultured for 18 hours. The extracellular cAMP levels were determined by specific radioimmunoassay as described by Davoren, J.B. et al. Biol
30 Reprod (1985) 33:37-52. In this assay, the wild-type had an ED_{50} of 0.6 ng/ml and the single-chain form had an ED_{50} of 1.7ng/ml. (ED_{50} is 50% of the effective dose.)

Thus, in all cases, the behavior of both the wild-type and single-chain forms is similar.

35

Example 3

Additional Activity Assays

The medium from CHO cells transfected with an expression vector for the β FSH-CTP- α single-chain construct was

- 33 -

recovered and assayed as described in Example 2. The results of the competition assay for binding to FSH receptor are shown in Figure 3. The results indicate that the single-chain form is more effective than either wild-type FSH or FSH containing a CTP extension at the β chain in inhibiting binding of FSH itself to the receptor. The ED_{50} for the single-chain form is approximately 50 mIU/ml while the ED_{50} for the extended heterodimer is somewhat over 100 mIU/ml. That for wild-type FSH is about 120 mIU/ml.

The results of the signal transduction assay are shown in Figure 4. The effectiveness of all three types of FSH is comparable.

Example 4

Construction of Additional Expression Vectors

In a manner similar to that set forth in Example 1, expression vectors for the production of single-stranded FSH, TSH and LH (β FSH- α , β FSH-CTP- α , β TSH- α , β TSH-CTP- α , β LH- α , β LH-CTP- α) are prepared and transfected into CHO cells. The resulting hormones show activities similar to those of the wild-type form, when assayed as set forth in Example 2.

Similarly, expression vectors for the "two- β " single-chain forms are constructed in a manner analogous to that set forth in Example 1 and expressed and assayed as described in Example 2.

Claims

1. A glycosylated or nonglycosylated protein which comprises:

the amino acid sequence of the α subunit common to the
5 glycoprotein hormones linked covalently, optionally through a linker moiety, to the amino acid sequence of the β subunit of one of said hormones,

wherein said α and β subunits consist of the native amino acid sequences or variants of said amino acid sequences.

10 2. The protein of claim 1 wherein said protein includes said linker moiety, and said linker moiety optionally includes a drug to be targeted to the receptor for the glycoprotein hormone.

3. The protein of claim 1 wherein a position
15 proximal to the C-terminus of the β subunit is linked covalently, optionally through a linker moiety, to a position proximal to the N-terminus of the α subunit, or wherein a position proximal to the C-terminus of the α subunit is linked covalently, optionally through a linker moiety, to a position
20 proximal to the N-terminus of the β subunit.

4. The protein of claim 1 wherein the β subunit is the β subunit of human chorionic gonadotropin or variant thereof; or

wherein the β subunit is the β subunit of FSH or
25 variant thereof; or

wherein the β subunit is the β subunit of FSH extended a position proximal to its C-terminus by a complete or partial CTP unit or variant thereof; or

wherein the β subunit is the β subunit of LH or
30 variant thereof; or

wherein the β subunit is the β subunit of LH extended at a position proximal to its C-terminus by a complete or partial CTP unit or variant thereof; or

wherein the β subunit is the β subunit of TSH or
35 variant thereof; or

- 35 -

wherein the β subunit is the β subunit of TSH extended at a position proximal to its C-terminus by a complete or partial CTP unit or variant thereof; and/or

wherein the α subunit is extended at a position
5 proximal to its N-terminus by a complete or partial CTP unit or variant thereof.

5. The protein of claim 1 wherein the α subunit or β subunit or both are modified by the insertion of a complete or partial CTP unit or variant thereof into a noncritical region
10 thereof and/or wherein said linker moiety includes a complete or partial CTP unit or variant thereof.

6. The protein of claim 5 wherein said partial CTP unit consists of positions 112-132; 115-132; 116-132; or 118-132; or 112-127; 115-127; 116-127; or 118-127; and/or
15 wherein said CTP has one or more O-linked glycosylation sites modified or deleted; and/or
wherein said noncritical region is proximal to the C-terminus; or
wherein said noncritical region is proximal to the N-
20 terminus.

7. The protein of claim 1 wherein the β subunit contains a modification in one or more N-linked glycosylation sites; and/or
wherein one or both of the N-linked glycosylation
25 sites of the α subunit have been modified; and/or
which is nonglycosylated; and/or
wherein one or more amino acids at positions 85-92 of the α subunit have been deleted.

8. A glycosylated or nonglycosylated protein which
30 comprises:

the amino acid sequence of the β subunit of a glycoprotein hormone linked covalently, optionally through a linker moiety, to the amino acid sequence of the β subunit of the same or different glycoprotein hormone,

wherein said β subunits consist of the native amino acid sequences of said hormones or variants of said amino acid sequences, or

the amino acid sequence of the α subunit of a
5 glycoprotein hormone linked covalently, optionally through a linker moiety, to the amino acid sequence of the α subunit of the same or different glycoprotein hormone,

wherein said α subunits consist of the native amino acid sequences of said hormones or variants of said amino acid
10 sequences.

9. The protein of claim 8 wherein a position proximal to the C-terminus of one α or β subunit is linked covalently, optionally through a linker moiety, to a position proximal to the N-terminus of the other α or β subunit.

15 10. The protein of claim 8 wherein said protein includes a linker moiety.

11. A pharmaceutical or veterinary composition which comprises the protein of claim 1 or 8 in admixture with a suitable pharmaceutical excipient.

20 12. Antibodies immunospecific for the protein of claim 1 or 8.

13. A DNA or RNA molecule which comprises a nucleotide sequence encoding the protein of claim 1 or 8.

25 14. An expression system for production of a single-chain form of a glycoprotein hormone which expression system comprises a first nucleotide sequence encoding the protein of claim 1 or 8 operably linked to control sequences capable of effecting the expression of said first nucleotide sequence.

30 15. The expression system of claim 14 which further contains a second nucleotide sequence encoding a signal peptide operably linked to the protein encoded by said first nucleotide sequence.

- 37 -


16. A host cell modified to contain the expression system of claim 15.

17. A method to produce a single-chain form of a glycoprotein hormone

5 which method comprises culturing the cells of claim 16 under conditions wherein said glycoprotein hormone is produced; and

recovering the glycoprotein hormone from the culture.

1 / 4



3 / 4




FIG. 3

4 / 4




FIG. 4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/09664

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/59, 16/26; C12P 21/00; C12N 5/10, 1/21, 15/16, 15/63

US CL : 530/350, 387.9; 435/69.7, 172.3, 240.2, 252.3, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350, 387.9; 435/69.7, 172.3, 240.2, 252.3, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE

search terms: hCG, LH, FSH, TSH, fusion protein, antibody

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Molecular and Cellular Endocrinology, Vol. 86, issued 1992, W. Chen et al., "Polyclonal antibodies against the polypeptide and carbohydrate epitopes of recombinant human choriogonadotropin β subunit", pages 57-66, entire document.	12
A	Proc. Nat. Acad. Sci. USA, Volume 85, issued August 1988, J.S. Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", pages 5879-5883, entire document.	1-11, 13-17
A	WO, A, 85/01959 (INTEGRATED GENETICS, INC.) 09 MAY 1985, entire document.	1-11, 13-17

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date as priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents and the combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document-number of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 19 OCTOBER 1995	Date of mailing of the international search report 20 NOV 1995
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer LORRAINE M. SPECTOR Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/09664

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 5,177,193 (BOIME ET AL.) 05 January 1993, entire document.	1-11, 13-17
A	US, A, 5,338,835 (BOIME) 16 August 1994, entire document.	1-11, 13-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/09664

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/09664

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-7, 11, 13-17, drawn to glycoprotein hormone $\alpha\beta$ fusion proteins.

Group II, claim(s) 8-10, 11, 13-17, drawn to drawn to glycoprotein hormone $\beta\beta$ fusion proteins.

Group III, claim(s) 12, drawn to anti glycoprotein hormone antibodies.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the proteins of Inventions I and II have distinct structures and properties, and are not so linked as to form a single inventive concept. The antibodies of Invention III share no structural or functional feature which is unique to either inventions I or II.